isoproterenol has been researched along with ciglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bachmann, W; Häring, HU; Kirsch, DM | 1 |
2 other study(ies) available for isoproterenol and ciglitazone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Ciglitazone reverses cAMP-induced post-insulin receptor resistance in rat adipocytes in vitro.
Topics: 3-O-Methylglucose; Adipose Tissue; Animals; Biological Transport; Cyclic AMP; Insulin; Insulin Resistance; Isoproterenol; Male; Methylglucosides; Rats; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1984 |